Literature DB >> 34594008

Response to: 'Comment on: 'Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae''.

Magdalena Popiela1,2, Michael Ardern-Jones3, Parwez Hossain4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34594008      PMCID： PMC9232652          DOI： 10.1038/s41433-021-01782-w

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   4.456


× No keyword cloud information.
  5 in total

1.  Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study.

Authors:  A T Touhouche; M Cassagne; E Bérard; F Giordano-Labadie; A Didier; P Fournié; C Paul; M Tauber
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-27       Impact factor: 6.166

Review 2.  Ocular surface disease associated with dupilumab treatment for atopic diseases.

Authors:  Canan Asli Utine; Gavin Li; Penny Asbell; Stephen Pflugfelder; Esen Akpek
Journal:  Ocul Surf       Date:  2020-05-18       Impact factor: 5.033

3.  Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.

Authors:  Alison D Treister; Cheryl Kraff-Cooper; Peter A Lio
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

4.  Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis.

Authors:  Adrien Maudinet; Sandrine Law-Koune; Claire Duretz; Audrey Lasek; Philippe Modiano; Thi Ha Chau Tran
Journal:  Ophthalmol Ther       Date:  2019-06-22

5.  Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae.

Authors:  Magdalena Z Popiela; Ramez Barbara; Andrew M J Turnbull; Emma Corden; Beatriz Suarez Martinez-Falero; Daniel O'Driscoll; Michael R Ardern-Jones; Parwez N Hossain
Journal:  Eye (Lond)       Date:  2021-01-28       Impact factor: 3.775
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.